Albendazole Oxide

Albendazole Oxide

SCHEMBL3175532

CCC[S+]([O-])c1ccc2[nH]c(NC(=O)OC)nc2c1.Cl

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Albendazole Oxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 known ✓ Q12809 1/20 0.50
KDR known ✓ P35968 3/20 0.44
ABL1 known ✓ P00519 1/20 0.44
PTGS1 known ✓ P23219 1/20 0.43
MAPK14 known ✓ Q16539 1/20 0.43
LMNA P02545 7/20 0.54
TUBB4A P04350 6/20 0.54
TUBB P07437 6/20 0.54
TUBA3C P0DPH7 6/20 0.54
TUBA1B P68363 6/20 0.54
TUBA4A P68366 6/20 0.54
TUBB4B P68371 6/20 0.54
TUBB3 Q13509 6/20 0.54
TUBB2A Q13885 6/20 0.54
TUBB8 Q3ZCM7 6/20 0.54
TUBA3E Q6PEY2 6/20 0.54
TUBA1A Q71U36 6/20 0.54
TUBA1C Q9BQE3 6/20 0.54
TUBB6 Q9BUF5 6/20 0.54
TUBB2B Q9BVA1 6/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Albendazole Oxide SCHEMBL321413 0.99 LMNA (0.55) LMNATUBB4ATUBBTUBA3CTUBA1B
Albendazole Oxide SCHEMBL29564405 0.99 LMNA (0.55) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11662850 0.90 LMNA (0.53) LMNATUBB4ATUBBTUBA3CTUBA1B
Albendazole Oxide SCHEMBL30580728 0.90 LMNA (0.64) LMNATUBB4ATUBBTUBA3CTUBA1B
Albendazole Oxide SCHEMBL1649240 0.90 LMNA (0.64) LMNATUBB4ATUBBTUBA3CTUBA1B
Albendazole Oxide SCHEMBL17968582 0.90 LMNA (0.64) LMNATUBB4ATUBBTUBA3CTUBA1B
Albendazole Oxide SCHEMBL9370388 0.89 LMNA (0.66) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10890981 0.87 NPC1 (0.43) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11266576 0.87 LMNA (0.45) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11213713 0.85 LMNA (0.47) LMNATUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113648322-A Ivermectin injection and preparation method thereof 哈尔滨绿达生动物药业有限公司 2021-11-16 CN claimed
CN-109431983-A A kind of compound ivermectin injection and preparation method thereof 合肥中龙神力动物药业有限公司 2019-03-08 CN claimed
US-20070053943-A1 Dimethicone-containing sustained release injection formulation WANG YUWAN 2007-03-08 US claimed
CN-1519234-A Preparation of hydrochloric albendazole sulfoxide 王玉万 2004-08-11 CN claimed
US-20240000752-A1 MICROSUSPENSION AGAINST PARASITES AND METHOD FOR OBTAINING SAME IPANEMA INDUSTRIA DE PRODUTOS VETERINARIOS LTDA (BR) 2024-01-04 US disclosed
EP-4230203-A1 MICROSUSPENSION AGAINST PARASITES AND METHOD FOR OBTAINING SAME Ipanema Industria de Produtos Veterinarios Ltda (BR) 2023-08-23 EP disclosed
CN-113648322-A Ivermectin injection and preparation method thereof 哈尔滨绿达生动物药业有限公司 2021-11-16 CN disclosed
CN-113648322-A Ivermectin injection and preparation method thereof 哈尔滨绿达生动物药业有限公司 2021-11-16 CN disclosed
CN-109431983-A A kind of compound ivermectin injection and preparation method thereof 合肥中龙神力动物药业有限公司 2019-03-08 CN disclosed
CN-109431983-A A kind of compound ivermectin injection and preparation method thereof 合肥中龙神力动物药业有限公司 2019-03-08 CN disclosed
US-10052341-B2 Method for preparing an anthelmintic composition, anthelmintic composition, veterinary treatment method and anthelmintic treatment method OURO FINO SAUDE ANIMAL PARTICIPACOES SA (BR) 2018-08-21 US disclosed
US-20160303157-A1 METHOD FOR PREPARING AN ANTHELMINTIC COMPOSITION, ANTHELMINTIC COMPOSITION, VETERINARY TREATMENT METHOD AND ANTHELMINTIC TREATMENT METHOD OURO FINO SAUDE ANIMAL PARTICIPACOES SA (BR) 2016-10-20 US disclosed
US-7648711-B2 Dimethicone-containing sustained release injection formulation WANG YUWAN 2010-01-19 US disclosed
US-20070053943-A1 Dimethicone-containing sustained release injection formulation WANG YUWAN 2007-03-08 US disclosed
CN-1522706-A Preparation of solid dispersoid containing large ring lactone parasite medicine 王玉万 2004-08-25 CN disclosed
CN-1518876-A Bactericide and insecticide in agricultural use containing albendazole sulfoxide and its salt 王玉万 2004-08-11 CN disclosed
CN-1519234-A Preparation of hydrochloric albendazole sulfoxide 王玉万 2004-08-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240000752-A1 MICROSUSPENSION AGAINST PARASITES AND METHOD FOR OBTAINING SAME MRPS35, MRPS27, RPS25 KCNH2 3425/4885KDR 4571/4885ABL1 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.